News and reporting on prostate cancer.
Simulations suggested prostate cancer screening informed by polygenic risk scores is more cost effective and less prone to overdiagnoses than screening based on age alone.
Palmetto has expanded the local coverage determination for the Guardant360 liquid biopsy assay to be used with the majority of advanced solid tumors.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The LCD will provide coverage for the Decipher Prostate Biopsy genomic test for men with both favorable and unfavorable intermediate-risk prostate cancer.
PWNHealth will enable Stratify to offer its Prompt Personal Genetic Score prostate cancer genetic risk test directly to consumers with medical oversight.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.
The San Diego-based company said that the number of commercial samples received during the quarter grew 66 percent year over year.
The company said revenues declined primarily as a result of adjustments in accounts receivable, payor mix, and the timing of test kit collections.
The number of technologies to be assessed is vast, and ranges from liquid biopsies and molecular imaging to immunohistochemistry and RNA-seq.
The company said it anticipates that more than 60 million Medicare beneficiaries will be covered for the ExoDx Prostate IntelliScore (EPI) test on Dec. 1.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.